Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens

References

• Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–150.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther. 2006;4(2):291–302.
   PubMedGoogle Scholar
• Shereen MA, Khan S, Kazmi A, et al. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–98.
   PubMed Web of Science ®Google Scholar
• Interim clinical guidance for patients suspected of/confirmed with COVID-19 in Belgium – 31 march 2020; version 6; 2020 [cited 2020 Apr 16]. Available from: https://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf
   Google Scholar
• Therapeutics and clinical trials. In: Brigham & Women’s Hospital COVID-19 Clinical Guidelines; 2020 [cited 2020 Apr 16]. Available from: https://covidprotocols.org/protocols/04-therapeutics-and-clinical-trials#systemic-corticosteroids
   Google Scholar
• Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 (fecha de actualización: 28 de marzo de 2020). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS); 2020 [cited 2020 Apr 9116]. Available from: https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%E2%80%9119/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-9112/?lang=en
   Google Scholar
• Medicamenteuze behandelopties bij patiënten met COVID-19 (infecties met SARS-CoV-2). Stichting Werkgroep Antibiotica Beleid (SWAB); 2020 [cited 2020 Apr 2016]. Available from: https://swab.nl/nl/article/nieuws/494/voorlopige-behandelopties-covid-419-infecties-met-sars-cov-492
   Google Scholar
• Vademecum per la cura delle persone con malattia da COVI-19. Società Italiana di Malattie Infettive e Tropicali; 2020 [cited 2020 Apr 1516]. Available from: http://www.simit.org/medias/1569-covid1519-vademecum-1513-1503-1202.pdf
   Google Scholar
• Liang T, editor. Handbook of COVID-19 prevention and treatment Zhejiang First Affiliated Hospital. Zhejiang, China: Zhejiang University School of Medicine; 2020.
   Google Scholar
• Thailand joins the WHO “Solidarity Trial”: global testing of effective treatments of COVID-19 across 8 countries – an aggressive effort to save lives from the pandemic. World Health Organization; 2020 [cited 2020 Apr 2016]. Available from: https://www.who.int/thailand/news/detail/20-03-2020-thailand-joins-the-who-solidarity-trial-global-testing-of-effective-treatments-of-covid-2019-across-2028-countries-an-aggressive-effort-to-save-lives-from-the-pandemic
   Google Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
   PubMed Web of Science ®Google Scholar
• Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122–1133.
   PubMed Web of Science ®Google Scholar
• Loukas A, Hotez PJ. Chemotherapy of helminth infections. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 11th ed. New York (NY): McGraw Hill; 2006. p. 1073–1093.
   Google Scholar
• British National Formulary 60. London (UK): BMJ Group/Pharmaceutical Press; 2010.
   Google Scholar
• Ivermectin (INCHEM Monograph); 1992 [cited 2020 Apr 16]. Available from: http://www.inchem.org/documents/pims/pharm/ivermect.htm
   Google Scholar
• Navarro M, Camprubí D, Requena-Méndez A, et al. Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020;75(4):827–834.
   PubMed Web of Science ®Google Scholar
• Krishna DR, Klotz U. Determination of ivermectin in human plasma by high-performance liquid chromatography. Arzneimittelforschung. 1993;43(5):609–611.
   PubMed Web of Science ®Google Scholar
• Long QC, Ren B, Li SX, et al. Human pharmacokinetics of orally taken ivermectin. Chin J Clin Pharmacol. 2001;17:203–206.
   Google Scholar
• Edwards G, Dingsdale A, Helsby N, et al. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur J Clin Pharmacol. 1988;35(6):681–684.
   PubMed Web of Science ®Google Scholar
• Ogbuokiri JE, Ozumba BC, Okonkwo PO. Ivermectin levels in human breastmilk. Eur J Clin Pharmacol. 1993;45(4):389–390.
   PubMed Web of Science ®Google Scholar
• Baraka OZ, Mahmoud BM, Marschke CK, et al. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50(5):407–410.
   PubMed Web of Science ®Google Scholar
• Elkassaby MH. Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus. Trop Med Parasitol. 1991;42(2):79–81.
   PubMedGoogle Scholar
• Okonkwo PO, Ogbuokiri JE, Ofoegbu E, et al. Protein binding and ivermectin estimations in patients with onchocerciasis. Clin Pharmacol Ther. 1993;53(4):426–430.
   PubMed Web of Science ®Google Scholar
• Njoo FL, Beek WM, Keukens HJ, et al. Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions. Am J Trop Med Hyg. 1995;52(1):94–97.
   PubMed Web of Science ®Google Scholar
• Muñoz J, Ballester MR, Antonijoan RM, et al. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS Negl Trop Dis. 2018;12(1):e0006020.
   PubMed Web of Science ®Google Scholar
• Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020;177:104760.
   PubMed Web of Science ®Google Scholar
• Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan equine encephalitis virus replication. Antiviral Res. 2013;100(3):662–672.
   PubMed Web of Science ®Google Scholar
• Tay MYF, Fraser JE, Chan WKK, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor ivermectin. Antiviral Res. 2013;99(3):301–306.
   PubMed Web of Science ®Google Scholar
• Colson P, Rolain JM, Lagier JC, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.
   PubMed Web of Science ®Google Scholar
• Thummel KE, Shen DD, Isoherannen N, et al. Appendix II. Design and optimization of dosage regimens. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 11th ed. New York (NY): McGraw Hill; 2006. p. 1787–1888.
   Google Scholar
• Shapiro TA, Goldberg DE. Chemotherapy of protozoal infections: malaria. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 11th ed. New York (NY): McGraw Hill; 2006. p. 1021–1047.
   Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. DOI: 10.1093/cid/ciaa237.
   Web of Science ®Google Scholar
• European Medicines Agency/178637/2020/Human Medicines Division. Summary on compassionate use – Remdesivir Gilead, International Nonproprietary Name: remdesivir, Procedure No. EMEA/H/K/5622/CU (03 Apr. 2020); 2020 [cited 2020 Apr 16]. Available from: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf
   Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Fawcett RS. Ivermectin use in scabies. Am Fam Physician. 2003;68(6):1089–1092.
   PubMed Web of Science ®Google Scholar
• Lespine A, Dupuy J, Orlowski S, et al. Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact. 2006;159(3):169–179.
   PubMed Web of Science ®Google Scholar
• Chaccour C, Hammann F, Ramón-García S, et al. Ivermectin and novel coronavirus disease (COVID-19): keeping rigor in times of urgency. Am J Trop Med Hyg. 2020. DOI: 10.4269/ajtmh.20-0271.
   PubMed Web of Science ®Google Scholar
• Götz V, Magar L, Dornfeld D, et al. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep. 2016;6:23138.
   PubMed Web of Science ®Google Scholar
• Nigeria records chloroquine poisoning after Trump endorses it for coronavirus treatment; 2020 [cited 2020 Apr 16]. Available from: https://edition.cnn.com/2020/03/23/africa/chloroquine-trump-nigeria-intl/index.html
   Google Scholar
• Jakhar D, Kaur I. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nat Med. 2020;26(5):632.
   PubMed Web of Science ®Google Scholar
• Veterinarians warn: do not buy ivermectin for treatment of humans, it is very toxic; 2020 [cited 2020 Apr 16]. Available from: https://news.bnt.bg/news/veterinari-preduprezhdavat-ne-kupuvaite-ivermektin-za-lechenie-na-hora-silno-toksichen-e-1047797news.html
   Google Scholar
• FDA letter to stakeholders: do not use ivermectin intended for animals as treatment for COVID-19 in humans (April 10, 2020); 2020 [cited 2020 Apr 16]. Available from: https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans
   Google Scholar
• Bray M, Rayner C, Noël F, et al. Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antiviral Res. 2020;178:104805.
   PubMed Web of Science ®Google Scholar
• Schmith VD, Zhou JJ, Lohmer LR. The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19. Clin Pharmacol Ther. 2020. DOI: 10.1002/cpt.1889.
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine: ClinicalTrials.gov.; 2020 [cited 2020 May 21]. Available from: https://clinicaltrials.gov/ct2/results?cond=covid-19&term=ivermectin&cntry=&state=&city=&dist=
   Google Scholar
• Patel AN, Desai SS, Grainger DW, Mehra MR. Usefulness of ivermectin in COVID-19 illness (April 19, 2020); 2020 [cited 2020 May 21]. Available from: https://ssrn.com/abstract=3580524
   Google Scholar